Q&A with Seth Karol, MD: Treating Pediatric Osteonecrosis

Video

Seth Karol, MD, St. Jude's Children's Research Center and his team focused their research on the 10-20 age group, the "sweet spot" where the bones are still finishing up development and thus going to be susceptible to therapy.

Seth Karol, MD, St. Jude's Children's Research Center and his team focused their research on the 10-20 age group, the "sweet spot" where the bones are still finishing up development and thus going to be susceptible to therapy.

"The more we know about the biology of the cancer we're trying to treat, the better we can try to separate the toxicity to the patient from the toxicity to the cancer, which is what we're aiming for," concluded Karol.

Related Videos
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Ankeet Bhatt, MD, MBA | Credit: X.com
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Veraprapas Kittipibul, MD | Credit: X.com
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
© 2024 MJH Life Sciences

All rights reserved.